Wynn Capital LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,185 shares of the company’s stock, valued at approximately $1,910,000. Johnson & Johnson accounts for 1.6% of Wynn Capital LLC’s holdings, making the stock its 16th biggest holding.
Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. South Dakota Investment Council increased its stake in shares of Johnson & Johnson by 8.1% during the 4th quarter. South Dakota Investment Council now owns 180,203 shares of the company’s stock worth $28,245,000 after purchasing an additional 13,525 shares in the last quarter. NewSquare Capital LLC increased its position in Johnson & Johnson by 46.7% during the fourth quarter. NewSquare Capital LLC now owns 760 shares of the company’s stock worth $119,000 after buying an additional 242 shares in the last quarter. First National Bank Sioux Falls raised its holdings in shares of Johnson & Johnson by 4.0% in the fourth quarter. First National Bank Sioux Falls now owns 5,242 shares of the company’s stock worth $822,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $2,800,000. Finally, Element Wealth LLC boosted its stake in shares of Johnson & Johnson by 5.1% during the fourth quarter. Element Wealth LLC now owns 1,428 shares of the company’s stock valued at $224,000 after acquiring an additional 69 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Trading Up 0.5 %
Shares of JNJ stock opened at $146.84 on Tuesday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The firm’s 50 day moving average price is $155.07 and its two-hundred day moving average price is $155.23. The stock has a market cap of $353.85 billion, a price-to-earnings ratio of 9.15, a price-to-earnings-growth ratio of 2.41 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 EPS. The business’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 29.68%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- Consumer Staples Stocks, Explained
- The 3 Hottest Insiders Buys This Month
- 3 Warren Buffett Stocks to Buy Now
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- How to Buy Cheap Stocks Step by Step
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.